Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study
Top Cited Papers
- 1 January 2008
- journal article
- gynecologic cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (1), 83-89
- https://doi.org/10.1200/jco.2007.13.1953
Abstract
Purpose To identify factors predictive of poor prognosis in a similarly treated population of women with stage IV epithelial ovarian cancer (EOC). Patients and Methods A retrospective review of 360...Keywords
This publication has 17 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-AnalysisJournal of Clinical Oncology, 2002
- Prognostic Factors of Stage IV Epithelial Ovarian Cancer: A Multicenter Retrospective StudyGynecologic Oncology, 2001
- Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Survival Impact of Surgical Cytoreduction in Stage IV Epithelial Ovarian CancerGynecologic Oncology, 1999
- Stage IV Ovarian Cancer: Impact of Surgical Debulking1Gynecologic Oncology, 1997
- Prognostic Significance of Residual Disease in Patients with Stage IV Epithelial Ovarian CancerGynecologic Oncology, 1997
- Effect of Surgical Debulking on Survival in Stage IV Ovarian CancerGynecologic Oncology, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinomaGynecologic Oncology, 1992